Chronic lead exposure induces fatty liver disease associated with the variations of gut microbiota DOI Creative Commons
Heng Wan, Yuying Wang, Haojie Zhang

et al.

Ecotoxicology and Environmental Safety, Journal Year: 2022, Volume and Issue: 232, P. 113257 - 113257

Published: Jan. 29, 2022

Lead (Pb) has been suggested as an endocrine-disrupting chemical. However, few studies have investigated the association between chronic Pb exposure and fatty liver disease.We aimed to investigate of with disease whether variations gut microbiota involve in mechanism induced by exposure.We conducted a cross-sectional study 3066 rural participants East China. Blood lead level (BLL) was detected, abdominal ultrasonography used diagnose hepatic steatosis. Both definition non-alcoholic (NAFLD) metabolic dysfunction-associated (MAFLD) were used. Wistar rats randomly divided into two groups each group exposed 0 or 0.05% w/v through drinking water for 28 weeks. The relevant parameters lipid metabolism analyzed.In humans, after adjusting potential confounders, odds having NAFLD MAFLD significantly increased 54% 52% fourth BLL quartile (OR 1.54, 95% CI 1.24, 1.91 OR 1.52, 1.22, 1.89). In rats, visceral fat, steatosis, dysbiosis microbiota, including decrease richness, diversity, evenness phylogenetic diversity significant alternations composition, particularly, relative abundance Coprococcus Oscillospira at genus level.Chronic could induce disease, which may be associated microbiota.

Language: Английский

Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach DOI
Giovanni Targher, Herbert Tilg, Christopher D. Byrne

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2021, Volume and Issue: 6(7), P. 578 - 588

Published: May 4, 2021

Language: Английский

Citations

377
MAFLD: How is it different from NAFLD? DOI Creative Commons
Cameron Gofton,

Yadhavan Upendran,

Ming‐Hua Zheng

et al.

Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 29(Suppl), P. S17 - S31

Published: Nov. 29, 2022

“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer related systemic metabolic dysregulation. The name change from nonalcoholic (NAFLD) MAFLD comes with a simple set of criteria enable easy diagnosis at bedside for general medical community, including primary care physicians. Since introduction term, there have been key areas which superiority over traditional NAFLD terminology has demonstrated, risk and extrahepatic mortality, associations, identifying high-risk individuals. Additionally, adopted by number leading pan-national national societies due its concise diagnostic criterion, removal requirement exclude concomitant diseases, reduction stigma associated this condition. current article explores differences between diagnosis, benefit, some potential limitations, how opened up new fields research.

Language: Английский

Citations

239
Global multi-stakeholder endorsement of the MAFLD definition DOI
Nahúm Méndez‐Sánchez, Elisabetta Bugianesi, Robert G. Gish

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2022, Volume and Issue: 7(5), P. 388 - 390

Published: March 3, 2022

Language: Английский

Citations

209
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement DOI
Mohammed Eslam, Naim Alkhouri, Pietro Vajro

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2021, Volume and Issue: 6(10), P. 864 - 873

Published: Aug. 6, 2021

Language: Английский

Citations

208
Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD DOI Creative Commons
Vy H. Nguyen, Michael H. Le, Ramsey Cheung

et al.

Clinical Gastroenterology and Hepatology, Journal Year: 2021, Volume and Issue: 19(10), P. 2172 - 2181.e6

Published: May 23, 2021

Language: Английский

Citations

175
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality DOI
Tom H. Karlsen, Nick Sheron, Shira Zelber‐Sagi

et al.

The Lancet, Journal Year: 2021, Volume and Issue: 399(10319), P. 61 - 116

Published: Dec. 2, 2021

Language: Английский

Citations

171
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight DOI
Mohammed Eslam, Hashem B. El–Serag, Sven Francque

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2022, Volume and Issue: 19(10), P. 638 - 651

Published: June 16, 2022

Language: Английский

Citations

165
Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults DOI Creative Commons
Jiaye Liu, Ibrahim Ayada, Xiaofang Zhang

et al.

Clinical Gastroenterology and Hepatology, Journal Year: 2021, Volume and Issue: 20(3), P. e573 - e582

Published: Feb. 21, 2021

Background & AimsMetabolic dysfunction-associated fatty liver disease (MAFLD) is a new terminology updated from non-alcoholic (NAFLD). In this study, we aim to estimate the global prevalence of MAFLD specifically in overweight and obese adults general population by performing systematic review meta-analysis through mining existing epidemiological data on disease.MethodsWe searched Medline, Embase, Web Science, Cochrane google scholar database inception November, 2020. DerSimonian-Laird random-effects model with Logit transformation was performed for analysis. Sensitivity analysis meta-regression were used explore predictors pooled statistics high heterogeneity.ResultsWe identified 116 relevant studies comprised 2,667,052 participants an estimated as 50.7% (95% CI 46.9-54.4) among overweight/obese regardless diagnostic techniques. Ultrasound most commonly technique generating rate 51.3% CI, 49.1-53.4). Male (59.0%; 95% 52.0-65.6) had significantly higher than female (47.5%; 40.7-54.5). Interestingly, rates are comparable based classical NAFLD non-NAFLD population. The comorbidities such type 2 diabetes metabolic syndrome 19.7% 12.8-29.0) 57.5% 49.9-64.8), respectively.ConclusionsMAFLD has astonishingly adults. This calls attention dedicated action primary care physicians, specialists, health policy makers public alike. Metabolic disease. We heterogeneity. respectively.

Language: Английский

Citations

163
Intestinal Barrier and Permeability in Health, Obesity and NAFLD DOI Creative Commons
Piero Portincasa, Leonilde Bonfrate, Mohamad Khalil

et al.

Biomedicines, Journal Year: 2021, Volume and Issue: 10(1), P. 83 - 83

Published: Dec. 31, 2021

The largest surface of the human body exposed to external environment is gut. At this level, intestinal barrier includes luminal microbes, mucin layer, gastrointestinal motility and secretion, enterocytes, immune cells, gut vascular barrier, liver barrier. A healthy characterized by selective permeability nutrients, metabolites, water, bacterial products, processes are governed cellular, neural, immune, hormonal factors. Disrupted (leaky syndrome) can represent a predisposing or aggravating condition in obesity metabolically associated steatosis (nonalcoholic fatty disease, NAFLD). In what follows, we describe morphological-functional features role major modifiers discuss recent evidence pointing key obesity/NAFLD.

Language: Английский

Citations

144
Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review DOI Creative Commons
Luca Rinaldi, Pia Clara Pafundi, Raffaele Galiero

et al.

Antioxidants, Journal Year: 2021, Volume and Issue: 10(2), P. 270 - 270

Published: Feb. 10, 2021

Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) are two different entities sharing common clinical physio-pathological features, with insulin resistance (IR) as the most relevant. Large evidence leads to consider it a risk factor for cardiovascular disease, regardless of age, sex, smoking habit, cholesterolemia, other elements MS. Therapeutic strategies remain still unclear, but lifestyle modifications (diet, physical exercise, weight loss) determine an improvement in IR, MS, both histologic picture. NAFLD IR bidirectionally correlated and, consequently, development pre-diabetes diabetes is direct consequence at extrahepatic level. In turn, type 2 well-known multiorgan damage, including involvement system, kidney peripheral nervous system. The increased MS incidence worldwide, above all due changes diet lifestyle, associated equally significant increase NAFLD, subsequent rise morbidity mortality metabolic, hepatic diseases. Therefore, slowdown "bad company" constituted by consequent indirect costs, represents one main challenges National Health Systems.

Language: Английский

Citations

138